Egrifta (Tesamorelin) EMA vs FDA: What Women Need to Know

The Core Regulatory Split: Why the FDA Said Yes and the EMA Never Did

The FDA approved tesamorelin in November 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, a recognized consequence of antiretroviral therapy. The EMA took a different path entirely. Theratechnologies submitted an application to the EMA, but withdrew it before a Committee for Medicinal Products for Human Use (CHMP) opinion was issued, meaning no formal European authorization ever existed. The agencies were working from the same key trial data but reached different conclusions about whether the benefit-risk balance warranted approval in a broader regulatory environment.

Understanding that split matters for any woman asking about tesamorelin, whether she is living with HIV, considering compounded peptides, or researching off-label GH-axis therapies.

What the FDA Based Its Decision On

The FDA reviewed two phase 3 randomized controlled trials, most prominently the Falutz et al. Study published in NEJM in 2007, which enrolled 412 HIV-positive adults with abdominal lipodystrophy. Participants receiving tesamorelin 2 mg daily for 26 weeks showed a statistically significant reduction in visceral adipose tissue (VAT) measured by CT scan compared with placebo. The mean VAT reduction was approximately 15% in the treatment arm versus a negligible change with placebo.

The FDA classified tesamorelin as a growth hormone-releasing hormone (GHRH) analog, not a growth hormone itself, which affected how the agency categorized its risk profile. The FDA prescribing label notes that the effect on VAT does not persist after discontinuation. Visceral fat returns toward baseline within 12 weeks of stopping the drug. This impermanence was a point the EMA flagged as relevant to long-term benefit-risk assessment.

Why the EMA Did Not Authorize

The EMA's CHMP had concerns centered on three areas: the clinical meaningfulness of VAT reduction as a surrogate endpoint, the absence of long-term cardiovascular outcome data, and questions about whether the European HIV-lipodystrophy population was sufficiently characterized. Because the application was withdrawn rather than rejected outright, there is no published EPAR (European Public Assessment Report) with a full CHMP opinion. That absence itself is informative. It signals that Theratechnologies and the CHMP were not aligned on what additional data would be required, and the sponsor chose not to proceed.

For women in the EU or UK, this means tesamorelin is not available through any authorized channel. In the US, it remains on-label for a specific HIV indication and off-label discussions are ongoing in obesity medicine and anti-aging contexts.

What the FDA Label Actually Says

The current Egrifta SV (tesamorelin) prescribing information is the authoritative document for US clinical use. Key label provisions that matter specifically for women are covered below.

Approved Indication and Dose

The approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approved dose is 2 mg administered subcutaneously once daily, injected into the abdomen, thighs, or upper arms. The injection site should be rotated.

There is no sex-specific dose adjustment on the label, but this reflects a gap in study design rather than confirmed dose equivalence between men and women. The original Falutz trials enrolled predominantly male participants, consistent with the HIV-positive population at the time of trial conduct. Women of reproductive age, pregnant women, and post-menopausal women were not studied as distinct subgroups with sufficient power to generate sex-stratified efficacy or safety data.

Contraindications Named on the Label

The FDA label lists the following contraindications:

• Pregnancy (see full discussion below)
• Disruption of the hypothalamic-pituitary axis, including hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma
• Active malignancy
• Known hypersensitivity to tesamorelin or mannitol

Active malignancy is an absolute contraindication because tesamorelin raises IGF-1, and IGF-1 promotes cell proliferation. Women with a personal history of breast cancer, ovarian cancer, or endometrial cancer should not use tesamorelin. This is not a theoretical concern. The FDA label explicitly states that any pre-existing malignancy must be treated and considered inactive before any off-label discussion could even begin.

Warnings and Precautions Relevant to Women

Glucose metabolism. Tesamorelin may cause glucose intolerance. Women with PCOS already carry elevated baseline risk for insulin resistance and type 2 diabetes. The label warns that tesamorelin should be used with caution in patients with diabetes or pre-diabetes, and glucose should be monitored. Women with PCOS who are also living with HIV-associated lipodystrophy face compounded metabolic risk that the label does not directly address, because that intersection was not studied.

Fluid retention. Like other GH-axis agents, tesamorelin can cause peripheral edema, arthralgias, and carpal tunnel syndrome. Women in perimenopause already experience joint pain and fluid shifts from declining estrogen. Separating tesamorelin-related symptoms from perimenopausal symptoms in clinical practice may be difficult.

IGF-1 monitoring. The label recommends monitoring IGF-1 levels. IGF-1 reference ranges differ by sex and age. Post-menopausal women have lower IGF-1 than premenopausal women of the same age, and estrogen therapy (particularly oral estrogen) further suppresses IGF-1. A post-menopausal woman on oral hormone therapy could have a blunted IGF-1 response to tesamorelin, making standard monitoring thresholds harder to interpret.

Sex-Specific Physiology: How Hormonal Status Changes the Drug's Effects

This section covers the physiology that the label does not fully address, because women were under-represented in the key trials.

Estrogen and the Growth Hormone Axis

Estrogen has a well-documented effect on GH secretion and IGF-1. Oral estrogen, in particular, increases GH secretion but simultaneously reduces hepatic IGF-1 production through a first-pass effect. Research in endocrinology journals has shown that women on oral estrogen require higher GH doses to achieve the same IGF-1 response as women not on estrogen or as men. Transdermal estrogen has a smaller effect on this axis because it bypasses hepatic first-pass metabolism.

For a post-menopausal woman using tesamorelin off-label, her route of estrogen therapy changes her IGF-1 response in a clinically meaningful way. A woman on oral conjugated equine estrogen may see a blunted IGF-1 rise compared with a woman on transdermal estradiol at a comparable dose. Clinicians monitoring IGF-1 as a proxy for tesamorelin response need to account for this.

The Menstrual Cycle and GH Pulsatility

In premenopausal women, GH is secreted in pulses that vary across the menstrual cycle. GH pulse amplitude is highest in the late follicular phase, when estrogen peaks. Tesamorelin acts by mimicking endogenous GHRH, so it superimposes on whatever background pulsatility the woman's cycle is generating. This could mean the drug's IGF-1 effect varies week to week in a cycling woman. No published trial has examined this. It is an evidence gap women deserve to know about.

PCOS and the GH/IGF-1 Axis

Women with PCOS show altered GH secretion patterns: more frequent but lower-amplitude pulses compared with controls. Some research suggests that hyperinsulinemia in PCOS directly suppresses GHRH receptor sensitivity. A woman with PCOS who develops HIV-associated lipodystrophy represents a clinically complex case where tesamorelin's effect on VAT reduction may differ from what was seen in the trial population.

The WomanRx framework for evaluating tesamorelin in women with concurrent hormonal conditions uses four questions that current labeling does not answer:

1. What is her estrogen route and dose, and how does it affect IGF-1 interpretation?
2. Does she have PCOS or insulin resistance that alters GH-axis sensitivity?
3. Is she in a reproductive life stage where IGF-1 elevation could affect ovarian function?
4. Does she have a personal or family history of hormone-sensitive cancer that makes IGF-1 elevation a net risk?

These questions should be part of any shared decision-making conversation before tesamorelin is prescribed or discussed.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory for any woman of reproductive age.

Pregnancy

Tesamorelin is contraindicated in pregnancy. Animal reproduction studies showed fetal harm. The drug has not been studied in human pregnancies, and given the IGF-1 elevation it produces, there is theoretical concern for fetal growth dysregulation. The FDA label states plainly that tesamorelin should be discontinued if a woman becomes pregnant. Under the prior FDA pregnancy category system (which the label used at the time of original approval), tesamorelin was designated Category X, meaning the risks outweigh any potential benefit and it must not be used in pregnancy.

Women living with HIV who are managing lipodystrophy and who are also trying to conceive need to plan ahead. Tesamorelin must be stopped before conception attempts, not just once a positive pregnancy test is confirmed.

Lactation

There are no human data on tesamorelin transfer into breast milk. The molecular weight of tesamorelin (approximately 5135 daltons) is large enough that transfer into milk may be limited, but this has not been studied. Given the lack of safety data and the theoretical risk of IGF-1-related effects in a nursing infant, tesamorelin should not be used while breastfeeding. Women should be counseled to pump and discard milk if tesamorelin is used for any reason, or to delay treatment until breastfeeding is complete.

Contraception Requirements

Because tesamorelin is contraindicated in pregnancy, all women of reproductive age using this drug must use reliable contraception. The label does not specify a preferred contraceptive method, but the clinical standard is a method with a failure rate below 1% with typical use, such as an IUD (copper or hormonal), implant, or consistent combined hormonal contraception. Note that hormonal contraceptives, particularly oral combined pills, will affect IGF-1 levels via the estrogen component, which adds another layer of complexity to monitoring.

Women using tesamorelin should have a confirmed negative pregnancy test before starting and should retest if a period is missed.

Who This Drug Is and Is Not Right For: A Life-Stage View

Women Living with HIV Who Are Not Pregnant or Breastfeeding

This is the only on-label population. A woman living with HIV who has documented lipodystrophy from antiretroviral therapy, no active malignancy, no hypothalamic-pituitary disruption, and who is not pregnant or nursing is the person this drug was studied in and approved for. Even in this population, female-specific subgroup data from the Falutz NEJM trial were not reported with the granularity needed to confirm that VAT reduction and safety outcomes were comparable to male participants.

Women Trying to Conceive

Tesamorelin is not appropriate during active attempts to conceive. The drug should be stopped at least one full menstrual cycle before trying, and longer washout may be advisable given uncertainty about IGF-1 normalization timelines.

Perimenopausal Women

Perimenopause brings irregular cycles, rising FSH, fluctuating estrogen, and often increasing visceral adiposity. Some women and clinicians have explored GH-axis peptides for body composition in this life stage. Tesamorelin has no approved indication here, no perimenopausal safety data, and the interaction between declining estrogen, IGF-1 dynamics, and the drug's mechanism has not been studied. Off-label use in this group is speculative and should be approached with substantial caution.

Post-Menopausal Women

Post-menopausal women have lower baseline IGF-1 and altered GH pulsatility. The concern about hormone-sensitive cancers is particularly relevant: post-menopausal women carry a higher absolute risk of breast and endometrial cancers, and any agent that raises IGF-1 warrants careful oncologic history review. Routine use outside an approved indication cannot be recommended based on available evidence.

Women with Active or Recent Malignancy

This is a hard contraindication. Women with a history of breast cancer, ovarian cancer, endometrial cancer, or any other IGF-1-sensitive tumor should not use tesamorelin. Period.

Post-Market Safety Surveillance: FDA Sentinel and Real-World Data

After approval, the FDA's active post-market surveillance system, FDA Sentinel, monitors for signals not detected in pre-approval trials. For tesamorelin, post-market surveillance has focused on glucose dysregulation, neoplasm signals, and injection-site reactions.

Because tesamorelin's approved population is defined by HIV status, real-world data come predominantly from HIV specialty clinics. Women represent a minority of HIV-positive patients in most US clinic databases, which means safety signals in women may be underpowered to detect. The CDC estimates that women account for approximately 19% of new HIV diagnoses in the United States. Even in the HIV-lipodystrophy population, women's representation in post-market surveillance databases likely mirrors or underperforms this figure.

No specific female-only safety signal has been formally announced in FDA Sentinel communications for tesamorelin as of the review date of this article. The absence of a signal here should not be read as a confirmed absence of risk. It may reflect insufficient surveillance of a minority subpopulation.

Glucose and Metabolic Monitoring Protocol for Women

Women starting tesamorelin should have a baseline fasting glucose and HbA1c before starting. Monitoring at 3 months and 6 months is consistent with the label's glucose precaution language. Women with PCOS, a personal history of gestational diabetes, or a BMI <27 with documented insulin resistance on labs deserve more frequent monitoring given their underlying risk architecture.

Off-Label Use, Compounded Tesamorelin, and the Regulatory Gray Zone

Tesamorelin has attracted interest in anti-aging and body-composition contexts well outside its approved indication. Compounded tesamorelin is available through some US pharmacies. The FDA has made clear that compounded versions of FDA-approved drugs do not carry the same safety and efficacy assurances as the approved product. Batch-to-batch consistency, sterility, and accurate dosing are not federally verified for compounded preparations.

Women seeking tesamorelin for off-label purposes should understand they are using a product with no regulatory endorsement for their specific indication, no sex-specific dosing data, no pregnancy safety data in humans, and a contraindication profile that includes conditions disproportionately common in women (hormone-sensitive cancers). The EMA's non-authorization adds weight to the argument that the benefit-risk profile outside the narrow HIV-lipodystrophy indication is not established.

Comparing the Regulatory Frameworks: FDA vs EMA Decision Architecture

The FDA and EMA share core principles around efficacy and safety but differ in how they weight surrogate endpoints and population generalizability.

Surrogate Endpoints and Clinical Meaningfulness

The FDA accepted VAT reduction by CT scan as a clinically meaningful surrogate endpoint for HIV-lipodystrophy. This was consistent with FDA's prior acceptance of body composition endpoints in HIV-related conditions. The EMA generally requires a stronger connection between a surrogate endpoint and patient-relevant outcomes, such as cardiovascular events or quality of life. VAT reduction without demonstrated cardiovascular benefit was harder to defend under European regulatory standards.

Population and Context Generalizability

The EMA also considers whether a drug will be used as studied in the European clinical environment. The European HIV population in 2010 had access to newer antiretroviral regimens that caused less lipodystrophy than older regimens common in the Falutz trial era. The CHMP may have concluded that the condition tesamorelin was meant to treat was becoming less prevalent in Europe, narrowing the potential benefit population further.

Post-Market Commitments

The FDA required post-market studies as a condition of approval. These post-market requirements included cardiovascular outcomes data and longer-term IGF-1 safety monitoring. Whether these requirements have been fully met and reported is a matter of ongoing FDA oversight documented in the agency's post-market database. Women and their clinicians can track this through Drugs@FDA.